{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:03:14Z","timestamp":1793520194475,"version":"4.5.0"},"reference-count":230,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:00:00Z","timestamp":1613779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Miss Sofia Kordolaimi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>MUC16 (the cancer antigen CA125) is the most commonly used serum biomarker in epithelial ovarian cancer, with increasing levels reflecting disease progression. It is a transmembrane glycoprotein with multiple isoforms, undergoing significant changes through the metastatic process. Aberrant glycosylation and cleavage with overexpression of a small membrane-bound fragment consist MUC16-related mechanisms that enhance malignant potential. Even MUC16 knockdown can induce an aggressive phenotype but can also increase susceptibility to chemotherapy. Variable MUC16 functions help ovarian cancer cells avoid immune cytotoxicity, survive inside ascites and form metastases. This review provides a comprehensive insight into MUC16 transformations and interactions, with description of activated oncogenic signalling pathways, and adds new elements on the role of its differential glycosylation. By following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer. Additionally, it presents proposed differences of MUC16 structure in normal\/benign conditions and epithelial ovarian malignancy.<\/jats:p>","DOI":"10.1093\/carcin\/bgab010","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T12:19:35Z","timestamp":1613391575000},"page":"327-343","source":"Crossref","is-referenced-by-count":66,"title":["The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0220-3368","authenticated-orcid":false,"given":"Panagiotis","family":"Giamougiannis","sequence":"first","affiliation":[{"name":"Department of Gynaecological Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"},{"name":"School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre L","family":"Martin-Hirsch","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK"},{"name":"Division of Cancer Sciences, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis L","family":"Martin","sequence":"additional","affiliation":[{"name":"Biocel UK Ltd, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"2021041713560278400_CIT0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"2021041713560278400_CIT0002","volume-title":"The World Ovarian Cancer Coalition Atlas","author":"Reid","year":"2018"},{"key":"2021041713560278400_CIT0003","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"2021041713560278400_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"2021041713560278400_CIT0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"2021041713560278400_CIT0006"},{"key":"2021041713560278400_CIT0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"2021041713560278400_CIT0008","first-page":"255","article-title":"Ovarian surface epithelium: biology, endocrinology, and pathology","volume":"22","author":"Auersperg","year":"2001","journal-title":"Endocr. Rev."},{"key":"2021041713560278400_CIT0009","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2021041713560278400_CIT0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/978-0-387-98094-2_15","article-title":"Microenvironmental regulation of ovarian cancer metastasis","volume":"149","author":"Barbolina","year":"2009","journal-title":"Cancer Treat. Res."},{"key":"2021041713560278400_CIT0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10585-008-9171-5","article-title":"Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression","volume":"25","author":"Hudson","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"2021041713560278400_CIT0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PGP.0b013e3181f45f3e","article-title":"The origin of ovarian carcinomas: a unifying hypothesis","volume":"30","author":"Auersperg","year":"2011","journal-title":"Int. J. Gynecol. Pathol."},{"key":"2021041713560278400_CIT0013","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.3892\/or_00000343","article-title":"Mesenchymal to epithelial transition in the human ovarian surface epithelium focusing on inclusion cysts","volume":"21","author":"Okamoto","year":"2009","journal-title":"Oncol. Rep."},{"key":"2021041713560278400_CIT0014","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(08)70277-8","article-title":"Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer","volume":"9","author":"Singh","year":"2008","journal-title":"Lancet Oncol."},{"key":"2021041713560278400_CIT0015","article-title":"The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance","volume":"11,838","author":"Loret","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2021041713560278400_CIT0016","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1073\/pnas.96.11.6249","article-title":"E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium","volume":"96","author":"Auersperg","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021041713560278400_CIT0017","article-title":"Complex determinants of epithelial: mesenchymal phenotypic plasticity in ovarian cancer","volume":"9,104","author":"Klymenko","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2021041713560278400_CIT0018","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J. Am. Coll. Surg."},{"key":"2021041713560278400_CIT0019","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/ijc.22840","article-title":"Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K\/Akt pathway in human ovarian carcinoma cells","volume":"121","author":"Lane","year":"2007","journal-title":"Int. J. Cancer"},{"key":"2021041713560278400_CIT0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"key":"2021041713560278400_CIT0021","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00404-013-3114-3","article-title":"The heterogeneity of ovarian cancer","volume":"289","author":"Meinhold-Heerlein","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"2021041713560278400_CIT0022","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"2021041713560278400_CIT0023","doi-asserted-by":"crossref","first-page":"76881","DOI":"10.18632\/oncotarget.20173","article-title":"PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state","volume":"8","author":"Alwosaibai","year":"2017","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0024","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"2021041713560278400_CIT0025","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"2021041713560278400_CIT0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"2021041713560278400_CIT0027","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/0008-5472.CAN-15-1050","article-title":"Understanding the unique attributes of MUC16 (CA125): potential implications in targeted therapy","volume":"75","author":"Das","year":"2015","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0028","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/biof.64","article-title":"Current status of mucins in the diagnosis and therapy of cancer","volume":"35","author":"Rachagani","year":"2009","journal-title":"Biofactors"},{"key":"2021041713560278400_CIT0029","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu. Rev. Physiol."},{"key":"2021041713560278400_CIT0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2021041713560278400_CIT0031","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1096\/fj.07-9673rev","article-title":"Structure, evolution, and biology of the MUC4 mucin","volume":"22","author":"Chaturvedi","year":"2008","journal-title":"FASEB J."},{"key":"2021041713560278400_CIT0032","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"2021041713560278400_CIT0033","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.18632\/oncotarget.2370","article-title":"Altered mucins (MUC) trafficking in benign and malignant conditions","volume":"5","author":"Joshi","year":"2014","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0034","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14728222.2018.1498845","article-title":"MUC16 as a novel target for cancer therapy","volume":"22","author":"Aithal","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"2021041713560278400_CIT0035","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1096\/fj.14-257352","article-title":"MUC16: molecular analysis and its functional implications in benign and malignant conditions","volume":"28","author":"Haridas","year":"2014","journal-title":"FASEB J."},{"key":"2021041713560278400_CIT0036","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.18632\/oncotarget.7652","article-title":"Tumor necrosis factor-\u03b1 and interferon-\u03b3 stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NF\u03baB","volume":"7","author":"Morgado","year":"2016","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000064032","article-title":"The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure","volume":"23","author":"O\u2019Brien","year":"2002","journal-title":"Tumour Biol."},{"issue":"12 Pt 1","key":"2021041713560278400_CIT0038","first-page":"6143","article-title":"Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas","volume":"46","author":"Davis","year":"1986","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0039","first-page":"207","article-title":"Detection of ovarian cancer marker CA 125 in human seminal plasma","volume":"6","author":"Halila","year":"1985","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000217821","article-title":"Purification and characterization of the CA 125 tumor-associated antigen from human ascites","volume":"14","author":"de los Frailes","year":"1993","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0041","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1155\/2010\/918457","article-title":"Conflicting views on the molecular structure of the cancer antigen CA125\/MUC16","volume":"28","author":"Bouanene","year":"2010","journal-title":"Dis. Markers"},{"key":"2021041713560278400_CIT0042","doi-asserted-by":"crossref","first-page":"10568","DOI":"10.3390\/ijms130810568","article-title":"Deciphering the molecular nature of ovarian cancer biomarker CA125","volume":"13","author":"Weiland","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"2021041713560278400_CIT0043","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000050600","article-title":"Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3","volume":"22","author":"Lloyd","year":"2001","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0044","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8","article-title":"Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule","volume":"71","author":"Lloyd","year":"1997","journal-title":"Int. J. Cancer"},{"key":"2021041713560278400_CIT0045","doi-asserted-by":"crossref","first-page":"9942","DOI":"10.3390\/ijms13089942","article-title":"Methods for identification of CA125 from ovarian cancer ascites by high resolution mass spectrometry","volume":"13","author":"Weiland","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"2021041713560278400_CIT0046","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","article-title":"Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125","volume":"2","author":"Kabawat","year":"1983","journal-title":"Int. J. Gynecol. Pathol."},{"key":"2021041713560278400_CIT0047","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1167\/iovs.02-0862","article-title":"MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope","volume":"44","author":"Arg\u00fceso","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021041713560278400_CIT0048","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1167\/iovs.07-0430","article-title":"Functions of MUC16 in corneal epithelial cells","volume":"48","author":"Blalock","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021041713560278400_CIT0049","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1167\/iovs.07-1081","article-title":"Release of membrane-associated mucins from ocular surface epithelia","volume":"49","author":"Blalock","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2021041713560278400_CIT0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00418-006-0246-6","article-title":"MUC16 in the lacrimal apparatus","volume":"127","author":"J\u00e4ger","year":"2007","journal-title":"Histochem. Cell Biol."},{"key":"2021041713560278400_CIT0051","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1095\/biolreprod.106.058347","article-title":"MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence","volume":"78","author":"Gipson","year":"2008","journal-title":"Biol. Reprod."},{"key":"2021041713560278400_CIT0052","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0897.2012.01113.x","article-title":"The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia","volume":"68","author":"Tyler","year":"2012","journal-title":"Am. J. Reprod. Immunol."},{"key":"2021041713560278400_CIT0053","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ajcp\/79.1.98","article-title":"Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types","volume":"79","author":"Kabawat","year":"1983","journal-title":"Am. J. Clin. Pathol."},{"key":"2021041713560278400_CIT0054","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12885-017-3417-z","article-title":"Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube","volume":"17","author":"Yang","year":"2017","journal-title":"BMC Cancer"},{"key":"2021041713560278400_CIT0055","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/modpathol.3800646","article-title":"Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)","volume":"19","author":"Chauhan","year":"2006","journal-title":"Mod. Pathol."},{"key":"2021041713560278400_CIT0056","doi-asserted-by":"crossref","first-page":"e26839","DOI":"10.1371\/journal.pone.0026839","article-title":"Pathobiological implications of MUC16 expression in pancreatic cancer","volume":"6","author":"Haridas","year":"2011","journal-title":"PLoS One"},{"key":"2021041713560278400_CIT0057","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/onc.2011.297","article-title":"MUC16 induced rapid G2\/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells","volume":"31","author":"Lakshmanan","year":"2012","journal-title":"Oncogene"},{"key":"2021041713560278400_CIT0058","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-16-2530","article-title":"MUC16 regulates TSPYL5 for lung cancer cell growth and chemoresistance by suppressing p53","volume":"23","author":"Lakshmanan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2021041713560278400_CIT0059","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.humpath.2007.09.009","article-title":"Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?","volume":"39","author":"Moritani","year":"2008","journal-title":"Hum. Pathol."},{"key":"2021041713560278400_CIT0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0061","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/1471-2407-14-234","article-title":"MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression","volume":"14","author":"Matte","year":"2014","journal-title":"BMC Cancer"},{"key":"2021041713560278400_CIT0062","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2011.02.020","article-title":"MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis","volume":"121","author":"Th\u00e9riault","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0063","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ejca.2011.07.004","article-title":"CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells","volume":"48","author":"Reinartz","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"2021041713560278400_CIT0064","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2009.08.007","article-title":"CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis","volume":"115","author":"Boivin","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.09.028","article-title":"CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish \u201cMALOVA\u201d Ovarian Cancer Study","volume":"104","author":"H\u00f8gdall","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0066","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0067","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2021041713560278400_CIT0068","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/172460089901400208","article-title":"Tissue quantification of CA 125 in epithelial ovarian cancer","volume":"14","author":"de la Cuesta","year":"1999","journal-title":"Int. J. Biol. Markers"},{"key":"2021041713560278400_CIT0069","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"2021041713560278400_CIT0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0090-8258(91)90087-L","article-title":"Does intraperitoneal CA-125 reflect disease status?","volume":"40","author":"Buller","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0071","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1525-1438.1997.00459.x","article-title":"Tumor tissue CA125 in ovarian carcinoma patients with normal serum levels","volume":"7","author":"Menczer","year":"1997","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0072","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1525-1438.2002.01007.x","article-title":"Tissue and serum CA125 expression in endometrial cancer","volume":"12","author":"Ginath","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0073","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO;2-K","article-title":"Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors","volume":"60","author":"Fleuren","year":"1987","journal-title":"Cancer"},{"key":"2021041713560278400_CIT0074","first-page":"4473","article-title":"TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms","volume":"17","author":"Har\u0142ozinska","year":"1997","journal-title":"Anticancer Res."},{"key":"2021041713560278400_CIT0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum. Reprod."},{"key":"2021041713560278400_CIT0076","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/cncr.24084","article-title":"The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study","volume":"115","author":"Zorn","year":"2009","journal-title":"Cancer"},{"key":"2021041713560278400_CIT0077","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0078","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1097-0142(19951115)76:10+<2004::AID-CNCR2820761317>3.0.CO;2-G","article-title":"Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers","volume":"76","author":"Skates","year":"1995","journal-title":"Cancer"},{"key":"2021041713560278400_CIT0079","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","article-title":"Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography","volume":"306","author":"Jacobs","year":"1993","journal-title":"BMJ"},{"key":"2021041713560278400_CIT0080","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"2021041713560278400_CIT0081","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"2021041713560278400_CIT0082","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"2021041713560278400_CIT0083","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0084","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0090-8258(89)90072-3","article-title":"Use of CA 125 monoclonal antibody to monitor patients with ovarian cancer","volume":"35","author":"Kudlacek","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0086","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0090-8258(89)90634-3","article-title":"A study of the monoclonal antibody OC 125 to diagnose malignant ovarian tumors","volume":"32","author":"Li","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0087","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2003.05.015","article-title":"Cancer antigen 125 associated with multiple benign and malignant pathologies","volume":"10","author":"Miralles","year":"2003","journal-title":"Ann. Surg. Oncol."},{"key":"2021041713560278400_CIT0088","doi-asserted-by":"crossref","first-page":"63963","DOI":"10.18632\/oncotarget.19246","article-title":"Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes","volume":"8","author":"Fang","year":"2017","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0089","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jcla.20323","article-title":"Cancer antigen 125 levels in inflammatory bowel diseases","volume":"23","author":"Ataseven","year":"2009","journal-title":"J. Clin. Lab. Anal."},{"key":"2021041713560278400_CIT0090","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.hlc.2010.08.001","article-title":"CA125\u2013a test with a change of heart","volume":"20","author":"Sikaris","year":"2011","journal-title":"Heart. Lung Circ."},{"key":"2021041713560278400_CIT0091","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/00365510701282326","article-title":"Serum tumour markers in patients with chronic kidney disease","volume":"67","author":"Xiaofang","year":"2007","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"2021041713560278400_CIT0092","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000441-198607000-00005","article-title":"Evaluation of serum CA125 values in healthy individuals and pregnant women","volume":"292","author":"Haga","year":"1986","journal-title":"Am. J. Med. Sci."},{"key":"2021041713560278400_CIT0093","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/172460089801300411","article-title":"CA 125 in benign gynecological conditions","volume":"13","author":"Meden","year":"1998","journal-title":"Int. J. Biol. Markers"},{"key":"2021041713560278400_CIT0094","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000050638","article-title":"The CA 125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O\u2019Brien","year":"2001","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0095","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1021\/pr500215g","article-title":"Characterization of binding epitopes of CA125 monoclonal antibodies","volume":"13","author":"Marcos-Silva","year":"2014","journal-title":"J. Proteome Res."},{"key":"2021041713560278400_CIT0096","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-05-3851","article-title":"Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the \u201ctip of the iceberg\u201d?","volume":"66","author":"Wahrenbrock","year":"2006","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0097","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int. J. Cancer"},{"key":"2021041713560278400_CIT0098","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0099","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2005.12.021","article-title":"Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 and MUC16","volume":"373","author":"Duraisamy","year":"2006","journal-title":"Gene"},{"key":"2021041713560278400_CIT0100","doi-asserted-by":"crossref","first-page":"28619","DOI":"10.1074\/jbc.M302741200","article-title":"Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125","volume":"278","author":"Kui Wong","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0101","first-page":"5011","article-title":"Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line","volume":"63","author":"Kohlgraf","year":"2003","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0102","doi-asserted-by":"crossref","first-page":"13174","DOI":"10.1074\/jbc.M309417200","article-title":"Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA125 (MUC16)","volume":"279","author":"Maeda","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0103","doi-asserted-by":"crossref","first-page":"9759","DOI":"10.1038\/srep09759","article-title":"Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi\/post-Golgi compartments","volume":"5","author":"Das","year":"2015","journal-title":"Sci. Rep."},{"key":"2021041713560278400_CIT0104","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/glycob\/cwx054","article-title":"Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16","volume":"27","author":"Gipson","year":"2017","journal-title":"Glycobiology"},{"key":"2021041713560278400_CIT0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1155\/2013\/917898","article-title":"OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain","volume":"34","author":"Bressan","year":"2013","journal-title":"Dis. Markers"},{"key":"2021041713560278400_CIT0106","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/glycob\/cwr182","article-title":"Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family","volume":"22","author":"Bennett","year":"2012","journal-title":"Glycobiology"},{"key":"2021041713560278400_CIT0107","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/978-1-4419-7877-6_25","article-title":"Mucin O-glycan branching enzymes: structure, function, and gene regulation","volume":"705","author":"Cheng","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"2021041713560278400_CIT0108","doi-asserted-by":"crossref","first-page":", a005199","DOI":"10.1101\/cshperspect.a005199","article-title":"Golgi glycosylation","volume":"3","author":"Stanley","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2021041713560278400_CIT0109","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbagen.2007.09.010","article-title":"Mucin-type O-glycosylation and its potential use in drug and vaccine development","volume":"1780","author":"Tarp","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"2021041713560278400_CIT0110","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tcb.2010.11.004","article-title":"Location, location, location: new insights into O-GalNAc protein glycosylation","volume":"21","author":"Gill","year":"2011","journal-title":"Trends Cell Biol."},{"key":"2021041713560278400_CIT0111","doi-asserted-by":"crossref","first-page":"742831","DOI":"10.1155\/2014\/742831","article-title":"Aberrant glycosylation as biomarker for cancer: focus on CD43","volume":"2014","author":"Tuccillo","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"2021041713560278400_CIT0112","doi-asserted-by":"crossref","first-page":"15636","DOI":"10.3390\/ijms140815636","article-title":"Exploring the glycosylation of serum CA125","volume":"14","author":"Saldova","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"2021041713560278400_CIT0113","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.molmed.2012.02.001","article-title":"Two opposing roles of O-glycans in tumor metastasis","volume":"18","author":"Tsuboi","year":"2012","journal-title":"Trends Mol. Med."},{"key":"2021041713560278400_CIT0114","doi-asserted-by":"crossref","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","article-title":"Immature truncated O-glycophenotype of cancer directly induces oncogenic features","volume":"111","author":"Radhakrishnan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021041713560278400_CIT0115","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","article-title":"Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc","volume":"68","author":"Ju","year":"2008","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0116","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/IGC.0000000000000965","article-title":"C1GALT1 seems to promote in vitro disease progression in ovarian cancer","volume":"27","author":"Chou","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0117","first-page":"4605","article-title":"Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas","volume":"61","author":"Schneider","year":"2001","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0118","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1023\/A:1007033218309","article-title":"Overexpression of alpha2,3 sialyltransferase in neuroblastoma cells results in an upset in the glycosylation process","volume":"16","author":"Georgopoulou","year":"1999","journal-title":"Glycoconj. J."},{"key":"2021041713560278400_CIT0119","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-1033.1995.607_2.x","article-title":"Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells","volume":"233","author":"Brockhausen","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"2021041713560278400_CIT0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2005.07.016","article-title":"Altered mRNA expressions of sialyltransferases in ovarian cancers","volume":"99","author":"Wang","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0121","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/ajcp\/96.6.711","article-title":"Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary","volume":"96","author":"Inoue","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"2021041713560278400_CIT0122","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0046-8177(94)90144-9","article-title":"Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors","volume":"25","author":"Tashiro","year":"1994","journal-title":"Hum. Pathol."},{"key":"2021041713560278400_CIT0123","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/gyno.1999.5708","article-title":"Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases\u2014a clinicopathologic study","volume":"77","author":"Davidson","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0124","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molonc.2014.10.005","article-title":"Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours","volume":"9","author":"Ricardo","year":"2015","journal-title":"Mol. Oncol."},{"key":"2021041713560278400_CIT0125","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0046-8177(97)90012-5","article-title":"Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationship with histopathology and prognosis","volume":"28","author":"Ghazizadeh","year":"1997","journal-title":"Hum. Pathol."},{"key":"2021041713560278400_CIT0126","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ajcp\/98.2.167","article-title":"Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas","volume":"98","author":"Yonezawa","year":"1992","journal-title":"Am. J. Clin. Pathol."},{"key":"2021041713560278400_CIT0127","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1021\/pr3010474","article-title":"Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer","volume":"12","author":"Chen","year":"2013","journal-title":"J. Proteome Res."},{"key":"2021041713560278400_CIT0128","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/IGC.0b013e3182473292","article-title":"Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer","volume":"22","author":"Akita","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"2021041713560278400_CIT0129","first-page":"4741","article-title":"Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity","volume":"52","author":"Ogata","year":"1992","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0130","doi-asserted-by":"crossref","first-page":"e72413","DOI":"10.1371\/journal.pone.0072413","article-title":"Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing","volume":"8","author":"Madsen","year":"2013","journal-title":"PLoS One"},{"key":"2021041713560278400_CIT0131","doi-asserted-by":"crossref","first-page":", 2045","DOI":"10.3390\/ijms19072045","article-title":"Mucins and truncated O-glycans unveil phenotypic discrepancies between serous ovarian cancer cell lines and primary tumours","volume":"19","author":"Coelho","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"2021041713560278400_CIT0132","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1053\/hupa.2000.9776","article-title":"Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions","volume":"31","author":"Davidson","year":"2000","journal-title":"Hum. Pathol."},{"key":"2021041713560278400_CIT0133","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1155\/2008\/601583","article-title":"Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis","volume":"25","author":"Saldova","year":"2008","journal-title":"Dis. Markers"},{"key":"2021041713560278400_CIT0134","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000217716","article-title":"Molecular nature and possible presence of a membranous glycan-phosphatidylinositol anchor of CA125 antigen","volume":"12","author":"Nagata","year":"1991","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0135","first-page":"412","article-title":"Bisecting N-acetylglucosamine on K562 cells suppresses natural killer cytotoxicity and promotes spleen colonization","volume":"56","author":"Yoshimura","year":"1996","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0136","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"Pt 7","key":"2021041713560278400_CIT0137","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1242\/jcs.00312","article-title":"The cancer antigen CA125 represents a novel counter receptor for galectin-1","volume":"116","author":"Seelenmeyer","year":"2003","journal-title":"J. Cell Sci."},{"key":"2021041713560278400_CIT0138","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1021\/acschembio.7b00305","article-title":"Antibodies against specific MUC16 glycosylation sites inhibit ovarian cancer growth","volume":"12","author":"Rao","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"2021041713560278400_CIT0139","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s001090050232","article-title":"Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death","volume":"76","author":"Perillo","year":"1998","journal-title":"J. Mol. Med. (Berl)."},{"key":"2021041713560278400_CIT0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s004320000207","article-title":"Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures","volume":"127","author":"Lahm","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2021041713560278400_CIT0141","first-page":"1389","article-title":"Concentrations of galectin-3 in the sera of normal controls and cancer patients","volume":"6","author":"Iurisci","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"2021041713560278400_CIT0142","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1096\/fj.11-195669","article-title":"Mucin 16 is a functional selectin ligand on pancreatic cancer cells","volume":"26","author":"Chen","year":"2012","journal-title":"FASEB J."},{"key":"2021041713560278400_CIT0143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/ol.2016.5431","article-title":"C-type lectins facilitate tumor metastasis","volume":"13","author":"Ding","year":"2017","journal-title":"Oncol. Lett."},{"key":"2021041713560278400_CIT0144","first-page":"2569","article-title":"The glycosylation landscape of pancreatic cancer","volume":"17","author":"Munkley","year":"2019","journal-title":"Oncol. Lett."},{"key":"2021041713560278400_CIT0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00428-016-1929-6","article-title":"Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors","volume":"468","author":"Ricardo","year":"2016","journal-title":"Virchows Arch."},{"key":"2021041713560278400_CIT0146","first-page":"1535","article-title":"Role of tumour markers in monitoring epithelial ovarian cancer","volume":"82","author":"Meyer","year":"2000","journal-title":"Br. J. Cancer"},{"key":"2021041713560278400_CIT0147","doi-asserted-by":"crossref","first-page":"e0193907","DOI":"10.1371\/journal.pone.0193907","article-title":"Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer","volume":"13","author":"Aithal","year":"2018","journal-title":"PLoS One"},{"key":"2021041713560278400_CIT0148","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/PAI.0b013e3181dbfcd2","article-title":"Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16","volume":"18","author":"Dharma Rao","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"2021041713560278400_CIT0149","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1515\/hsz-2014-0155","article-title":"Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16\/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium","volume":"395","author":"Bruney","year":"2014","journal-title":"Biol. Chem."},{"key":"2021041713560278400_CIT0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/172460089801300406","article-title":"Regulation of CA 125 expression in cultured human carcinoma cells","volume":"13","author":"Marth","year":"1998","journal-title":"Int. J. Biol. Markers"},{"key":"2021041713560278400_CIT0151","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1006\/gyno.1996.0253","article-title":"Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125","volume":"62","author":"Zeimet","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0152","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s12885-019-5611-7","article-title":"Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway","volume":"19","author":"Matte","year":"2019","journal-title":"BMC Cancer"},{"key":"2021041713560278400_CIT0153","first-page":"3502","article-title":"Hormonal regulation of CA125 tumor marker expression in human ovarian carcinoma cells: inhibition by glucocorticoids","volume":"48","author":"Karlan","year":"1988","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0154","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark. Med."},{"key":"2021041713560278400_CIT0155","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/172460089801300403","article-title":"More than 15 years of CA 125: what is known about the antigen, its structure and its function","volume":"13","author":"O\u2019Brien","year":"1998","journal-title":"Int. J. Biol. Markers"},{"key":"2021041713560278400_CIT0156","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000218041","article-title":"CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line","volume":"18","author":"Fendrick","year":"1997","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0157","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/107155769400100118","article-title":"Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line","volume":"1","author":"Konishi","year":"1994","journal-title":"J. Soc. Gynecol. Investig."},{"key":"2021041713560278400_CIT0158","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/emboj.2012.150","article-title":"The many faces and functions of \u03b2-catenin","volume":"31","author":"Valenta","year":"2012","journal-title":"EMBO J."},{"key":"2021041713560278400_CIT0159","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/bjc.2011.34","article-title":"Downregulation of cell surface CA125\/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells","volume":"104","author":"Comamala","year":"2011","journal-title":"Br. J. Cancer"},{"key":"2021041713560278400_CIT0160","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejcb.2013.10.005","article-title":"CA125\/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion","volume":"92","author":"Akita","year":"2013","journal-title":"Eur. J. Cell Biol."},{"key":"2021041713560278400_CIT0161","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1038\/onc.2017.171","article-title":"Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis","volume":"36","author":"Klymenko","year":"2017","journal-title":"Oncogene"},{"key":"2021041713560278400_CIT0162","doi-asserted-by":"crossref","first-page":"e0184439","DOI":"10.1371\/journal.pone.0184439","article-title":"E-cadherin: a determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness","volume":"12","author":"Rosso","year":"2017","journal-title":"PLoS One"},{"key":"2021041713560278400_CIT0163","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.neo.2017.04.002","article-title":"Heterogeneous cadherin expression and multicellular aggregate dynamics in ovarian cancer dissemination","volume":"19","author":"Klymenko","year":"2017","journal-title":"Neoplasia"},{"key":"2021041713560278400_CIT0164","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial-mesenchymal transitions in tumour progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2021041713560278400_CIT0165","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1172\/JCI69815","article-title":"Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance","volume":"124","author":"Davidowitz","year":"2014","journal-title":"J. Clin. Invest."},{"key":"2021041713560278400_CIT0166","first-page":"219","article-title":"MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering \u03b2-catenin signaling","volume":"5","author":"Giannakouros","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"2021041713560278400_CIT0167","doi-asserted-by":"crossref","first-page":"36800","DOI":"10.18632\/oncotarget.9191","article-title":"C-terminus of MUC16 activates Wnt signaling pathway through its interaction with \u03b2-catenin to promote tumorigenesis and metastasis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0168","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000453594","article-title":"Transmembrane mucins: signaling receptors at the intersection of inflammation and cancer","volume":"9","author":"van Putten","year":"2017","journal-title":"J. Innate Immun."},{"key":"2021041713560278400_CIT0169","doi-asserted-by":"crossref","first-page":"967","DOI":"10.18632\/oncotarget.13514","article-title":"Unconjugated secondary bile acids activate the unfolded protein response and induce Golgi fragmentation via a src-kinase-dependant mechanism","volume":"8","author":"Sharma","year":"2017","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0170","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2021041713560278400_CIT0171","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/ncb758","article-title":"Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex","volume":"4","author":"Fujita","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"2021041713560278400_CIT0172","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1038\/cddis.2013.442","article-title":"An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)","volume":"4","author":"Huang","year":"2013","journal-title":"Cell Death Dis."},{"key":"2021041713560278400_CIT0173","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.274.51.36734","article-title":"Regulation of E-cadherin\/catenin association by tyrosine phosphorylation","volume":"274","author":"Roura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0174","doi-asserted-by":"crossref","first-page":", 34","DOI":"10.3390\/biom6030034","article-title":"Functional consequences of differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)","volume":"6","author":"Hanson","year":"2016","journal-title":"Biomolecules"},{"key":"2021041713560278400_CIT0175","doi-asserted-by":"crossref","first-page":"e0126633","DOI":"10.1371\/journal.pone.0126633","article-title":"Expression of the carboxy-terminal portion of MUC16\/CA125 induces transformation and tumor invasion","volume":"10","author":"Rao","year":"2015","journal-title":"PLoS One"},{"key":"2021041713560278400_CIT0176","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/ijo.2014.2707","article-title":"Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail","volume":"46","author":"Giannakouros","year":"2015","journal-title":"Int. J. Oncol."},{"key":"2021041713560278400_CIT0177","first-page":"2172","article-title":"The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines","volume":"63","author":"Grille","year":"2003","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0178","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbrc.2009.03.088","article-title":"PI3 kinase\/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells","volume":"382","author":"Yan","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021041713560278400_CIT0179","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1535-6108(02)00150-2","article-title":"A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor","volume":"2","author":"Suyama","year":"2002","journal-title":"Cancer Cell"},{"key":"2021041713560278400_CIT0180","doi-asserted-by":"crossref","first-page":", 52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2021041713560278400_CIT0181","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","article-title":"Integrin-regulated FAK-Src signaling in normal and cancer cells","volume":"18","author":"Mitra","year":"2006","journal-title":"Curr. Opin. Cell Biol."},{"key":"2021041713560278400_CIT0182","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/onc.2012.127","article-title":"Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells","volume":"32","author":"Cheng","year":"2013","journal-title":"Oncogene"},{"key":"2021041713560278400_CIT0183","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"2021041713560278400_CIT0184","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","article-title":"The cell-cell adhesion molecule E-cadherin","volume":"65","author":"van Roy","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"2021041713560278400_CIT0185","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P","article-title":"beta-catenin signaling and cancer","volume":"21","author":"Morin","year":"1999","journal-title":"Bioessays"},{"key":"2021041713560278400_CIT0186","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12885-019-5371-4","article-title":"MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"2021041713560278400_CIT0187","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.18632\/oncotarget.3308","article-title":"Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells","volume":"6","author":"Das","year":"2015","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0188","first-page":"5772","article-title":"JAK2\/STAT3 pathway as a therapeutic target in ovarian cancers","volume":"15","author":"Yoshikawa","year":"2018","journal-title":"Oncol. Lett."},{"key":"2021041713560278400_CIT0189","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/sj.emboj.7600136","article-title":"E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases","volume":"23","author":"Qian","year":"2004","journal-title":"EMBO J."},{"key":"2021041713560278400_CIT0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"2021041713560278400_CIT0191","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.canlet.2006.03.029","article-title":"Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery","volume":"247","author":"Scholler","year":"2007","journal-title":"Cancer Lett."},{"key":"2021041713560278400_CIT0192","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Kaneko","year":"2009","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0193","doi-asserted-by":"crossref","first-page":"1010428318804937","DOI":"10.1177\/1010428318804937","article-title":"Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients","volume":"40","author":"Ok\u0142a","year":"2018","journal-title":"Tumour Biol."},{"key":"2021041713560278400_CIT0194","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40291-017-0255-2","article-title":"Correlation between tumor mesothelin expression and serum mesothelin in patients with epithelial ovarian carcinoma: a potential noninvasive biomarker for mesothelin-targeted therapy","volume":"21","author":"Hanaoka","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"2021041713560278400_CIT0195","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","article-title":"Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas","volume":"34","author":"Frierson","year":"2003","journal-title":"Hum. Pathol."},{"key":"2021041713560278400_CIT0196","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2003.12.034","article-title":"Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers","volume":"93","author":"Burleson","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0197","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1006\/gyno.1999.5388","article-title":"Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro","volume":"73","author":"Strobel","year":"1999","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0198","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0002-9440(10)65406-5","article-title":"CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells","volume":"154","author":"Lessan","year":"1999","journal-title":"Am. J. Pathol."},{"key":"2021041713560278400_CIT0199","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-06-2808","article-title":"Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells","volume":"67","author":"Symowicz","year":"2007","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0200","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1074\/jbc.M608428200","article-title":"Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression","volume":"282","author":"Barbolina","year":"2007","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0201","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/cas.13134","article-title":"Activation of MMP-9 by membrane type-1 MMP\/MMP-2 axis stimulates tumor metastasis","volume":"108","author":"Li","year":"2017","journal-title":"Cancer Sci."},{"key":"2021041713560278400_CIT0202","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"2021041713560278400_CIT0203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"2021041713560278400_CIT0204","doi-asserted-by":"crossref","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2021041713560278400_CIT0205","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/0008-5472.CAN-06-2264","article-title":"DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells","volume":"67","author":"Carlsten","year":"2007","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0206","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/imt.11.20","article-title":"Immunity and immune suppression in human ovarian cancer","volume":"3","author":"Preston","year":"2011","journal-title":"Immunotherapy"},{"key":"2021041713560278400_CIT0207","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.coi.2004.07.010","article-title":"Killer immunoglobulin-like receptors","volume":"16","author":"Moretta","year":"2004","journal-title":"Curr. Opin. Immunol."},{"key":"2021041713560278400_CIT0208","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nri1306","article-title":"Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future","volume":"4","author":"Vivier","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"2021041713560278400_CIT0209","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2567.2007.02660.x","article-title":"Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)","volume":"122","author":"Belisle","year":"2007","journal-title":"Immunology"},{"key":"2021041713560278400_CIT0210","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2005.05.002","article-title":"Complement-inhibiting effect of ovarian cancer antigen CA-125","volume":"236","author":"Murdoch","year":"2006","journal-title":"Cancer Lett."},{"key":"2021041713560278400_CIT0211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-9-11","article-title":"MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells","volume":"9","author":"Gubbels","year":"2010","journal-title":"Mol. Cancer"},{"key":"2021041713560278400_CIT0212","first-page":"2229","article-title":"Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells","volume":"59","author":"Komatsu","year":"1999","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0213","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.4049\/jimmunol.174.4.2376","article-title":"Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism","volume":"174","author":"Vasir","year":"2005","journal-title":"J. Immunol."},{"key":"2021041713560278400_CIT0214","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.4049\/jimmunol.173.11.6841","article-title":"The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells","volume":"173","author":"Avril","year":"2004","journal-title":"J. Immunol."},{"key":"2021041713560278400_CIT0215","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-4598-9-118","article-title":"Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes","volume":"9","author":"Belisle","year":"2010","journal-title":"Mol. Cancer"},{"key":"2021041713560278400_CIT0216","doi-asserted-by":"crossref","first-page":"43117","DOI":"10.1074\/jbc.M403538200","article-title":"Negative regulation of T cell receptor signaling by Siglec-7 (p70\/AIRM) and Siglec-9","volume":"279","author":"Ikehara","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021041713560278400_CIT0217","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.dci.2018.05.008","article-title":"Siglecs: a journey through the evolution of sialic acid-binding immunoglobulin-type lectins","volume":"86","author":"Bornh\u00f6fft","year":"2018","journal-title":"Dev. Comp. Immunol."},{"key":"2021041713560278400_CIT0218","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ygyno.2005.07.030","article-title":"Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125","volume":"99","author":"Patankar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"2021041713560278400_CIT0219","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.143.10.3183","article-title":"Comparative studies of human FcRIII-positive and negative natural killer cells","volume":"143","author":"Nagler","year":"1989","journal-title":"J. Immunol."},{"key":"2021041713560278400_CIT0220","first-page":"161","article-title":"Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma","volume":"2","author":"Lai","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"2021041713560278400_CIT0221","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/hyb.1999.18.47","article-title":"Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID\/BG mouse model","volume":"18","author":"Schultes","year":"1999","journal-title":"Hybridoma"},{"key":"2021041713560278400_CIT0222","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hyb.1995.14.167","article-title":"A monoclonal antiidiotypic antibody ACA 125 mimicking the tumor-associated antigen CA 125 for immunotherapy of ovarian cancer","volume":"14","author":"Schlebusch","year":"1995","journal-title":"Hybridoma"},{"key":"2021041713560278400_CIT0223","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1158\/0008-5472.CAN-06-4512","article-title":"Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"2021041713560278400_CIT0224","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7150\/jca.2.280","article-title":"HN125: a novel immunoadhesin targeting MUC16 with potential for cancer therapy","volume":"2","author":"Xiang","year":"2011","journal-title":"J. Cancer"},{"key":"2021041713560278400_CIT0225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2407-14-35","article-title":"Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3","volume":"14","author":"Garg","year":"2014","journal-title":"BMC Cancer"},{"key":"2021041713560278400_CIT0226","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.18632\/oncotarget.8925","article-title":"Mesothelin\u2019s minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"2021041713560278400_CIT0227","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2021041713560278400_CIT0228","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"2021041713560278400_CIT0229","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2014the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"2021041713560278400_CIT0230","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1093\/annonc\/mdw401","article-title":"Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer","volume":"27","author":"Liu","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/advance-article-pdf\/doi\/10.1093\/carcin\/bgab010\/36645313\/bgab010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/42\/3\/327\/37119068\/bgab010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/42\/3\/327\/37119068\/bgab010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T07:11:12Z","timestamp":1697872272000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/42\/3\/327\/6145151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,20]]},"references-count":230,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,2,20]]},"published-print":{"date-parts":[[2021,4,17]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgab010","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,2,20]]}}}